Cryptococcosis (Infectious Disease) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cryptococcosis (Infectious Disease) – Drugs In Development, 2021, provides an overview of the Cryptococcosis (Infectious Disease) pipeline landscape.

Cryptococcosis is infection caused by Cryptococcus neoformans fungus. Symptoms include cough, fatigue, fever, head ache, nausea and skin rashes. Predisposing factors are most often seen in people with a weakened immune system, such as those with HIV infection, taking high doses of corticosteroid medications, cancer chemotherapy, or who have Hodgkin's disease. Treatment includes anti fungal drugs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cryptococcosis (Infectious Disease) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Cryptococcosis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cryptococcosis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cryptococcosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase I, Preclinical and Discovery stages are 1, 2, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Cryptococcosis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Cryptococcosis (Infectious Disease).

– The pipeline guide reviews pipeline therapeutics for Cryptococcosis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Cryptococcosis (Infectious Disease) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Cryptococcosis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Cryptococcosis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Cryptococcosis (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Cryptococcosis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

Amtixbio Co Ltd

Basilea Pharmaceutica Ltd

Collaborations Pharmaceuticals Inc

iNtRON Biotechnology Inc

MicroRid Technologies Inc

Novabiotics Ltd

Pfizer Inc

Pulmocide Ltd

Pulmonomy Inc

Visterra Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Cryptococcosis - Overview

Cryptococcosis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Cryptococcosis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Cryptococcosis - Companies Involved in Therapeutics Development

Amtixbio Co Ltd

Basilea Pharmaceutica Ltd

Collaborations Pharmaceuticals Inc

iNtRON Biotechnology Inc

MicroRid Technologies Inc

Novabiotics Ltd

Pfizer Inc

Pulmocide Ltd

Pulmonomy Inc

Visterra Inc

Cryptococcosis - Drug Profiles

Drugs for Cryptococcosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fosmanogepix - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

iNEYD-34 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

isavuconazonium sulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NP-339 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PC-1244 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Cryptococcosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TCPMY-123 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Glucosylceramide for Fungal Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VIS-FNG - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VT-1598 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Cryptococcosis - Dormant Projects

Cryptococcosis - Discontinued Products

Cryptococcosis - Product Development Milestones

Featured News & Press Releases

Sep 09, 2019: FDA grants Fast Track Status to Amplyx Pharmaceuticals for IV and Oral Formulations of Fosmanogepix (APX001) for seven different indications

Feb 11, 2019: FDA grants orphan drug designation to Amplyx Pharmaceuticals for APX001 for treatment of cryptococcosis

Apr 18, 2018: Basilea reports start of clinical phase 3 study in Japan by Asahi Kasei Pharma with antifungal isavuconazole

Mar 12, 2018: Amplyx Pharmaceuticals Receives Fourth Qualified Infectious Disease Product Designation from the FDA for APX001

Jun 27, 2016: New Promise Against Deadly Global Fungal Infections

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Cryptococcosis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Cryptococcosis – Pipeline by Amtixbio Co Ltd, 2021

Cryptococcosis – Pipeline by Basilea Pharmaceutica Ltd, 2021

Cryptococcosis – Pipeline by Collaborations Pharmaceuticals Inc, 2021

Cryptococcosis – Pipeline by iNtRON Biotechnology Inc, 2021

Cryptococcosis – Pipeline by MicroRid Technologies Inc, 2021

Cryptococcosis – Pipeline by Novabiotics Ltd, 2021

Cryptococcosis – Pipeline by Pfizer Inc, 2021

Cryptococcosis – Pipeline by Pulmocide Ltd, 2021

Cryptococcosis – Pipeline by Pulmonomy Inc, 2021

Cryptococcosis – Pipeline by Visterra Inc, 2021

Cryptococcosis – Dormant Projects, 2021

Cryptococcosis – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Cryptococcosis, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports